The model combines measurable parameters—namely, the metabolic tumor volume and the metabolic heterogeneity, from baseline PET/CT with the presence or absence of mutations in SOCS1 and CREBBP/EP300 and represents a promising tool for the design of clinical trials focused on tailoring treatment to the individual risk. Here, EP300 is linked to neoplasm.